The Oncogenic Palmitoyi-Protein Network in Prostate Cancer
Abstract
Epidemiologica l data indicate that cholesterol-lowering pharmacotherapy, primarily HGM-CoA-reductase inhibitors ("status"), reduce the risk of aggressive prostate cancer (PCa). The FDA-approved anti obesity drug, Ortistat, which inhibits the enzyme fatty acid synthase (FASN), has been shown to slow the growth of human prostate tumors in mice. Despite these advances, studies of lipid metabolism in PCa have lagged behind other areas of research on cell signaling, and limited information is available about how these promising preclinical and clinical data might be leveraged to improve patient outcomes. Our hypothesis is that PCa progression is dependent on a palmitoyl-protein network regulated by FASN. We predict that the activity of this network can be suppressed by reducing levels of circulating cholesterol. Specific Aims: We will challenge this hypothesis with the following specific A; Identify critical palmitoyl-proteins in the FASN subnetwork.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2014
- Accession Number
- ADA610716
Entities
People
- Michael R Freeman
Organizations
- Cedars-Sinai Medical Center